Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chlamydia protein Pgp3 in preparation of medicine for inhibiting salpingitis

A chlamydia protein, fallopian tube technology, applied in the field of biomedicine, can solve problems such as ambiguity

Pending Publication Date: 2022-03-15
GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the current research status is not yet clear about how pgp3 causes tubal inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlamydia protein Pgp3 in preparation of medicine for inhibiting salpingitis
  • Application of chlamydia protein Pgp3 in preparation of medicine for inhibiting salpingitis
  • Application of chlamydia protein Pgp3 in preparation of medicine for inhibiting salpingitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] The construction of embodiment 1 experimental mouse model

[0037] 1.1 Preparation of experimental animals

[0038] 20 C3H / HeJ female mice of SPF grade, weighing 18-20 g and aged 5-6 weeks were raised.

[0039] 1.2 Experimental grouping and intervention

[0040] 20 mice were randomly divided into 4 groups, 5 in each group, i.e. blank group (without any treatment), negative control group (i.e. CT795 group), high concentration group (His-pgp3 concentration is 10 μg / μl), low concentration group (His-pgp3 concentration was 1 μg / μl).

[0041] (1) Dilute the purified His-pgp3 to 10 μg / μl and 1 μg / μl with sterile PBS liquid.

[0042] (2) Inject His-pgp3 (10 μg / μl, 10 μl) into the left and right ovaries of each mouse in the high concentration group, that is, inject 100 μg of His-pgp3 into the left and right ovaries of each mouse.

[0043] (3) Inject His-pgp3 (1 μg / μl, 10 μl) into the left and right ovaries of each mouse in the low concentration group, that is, inject 10 μg ...

Embodiment 2

[0052] Example 2 Affinity Detection of His-pgp3, TNF-α and TNFR1

[0053] Using the amino acid coupling method, the diluted His-Pgp3 was immobilized on the activated CM5 chip. TNF-α and TNFR1 were injected into the channel with different concentration gradients, and the signal intensity was detected. All signals are corrected via a blank channel. Analytical processing was performed with Biacore 3000 Control Software.

[0054] image 3 Kinetic analysis diagram of His-pgp3 pair coupled antibody TNF-α, Figure 4 Kinetic analysis diagram of His-pgp3 pair coupled antibody TNFR1, by image 3 with Figure 4 It can be seen that as the concentration of TNF-α increases, the signal value increases, with a certain saturation trend, and the KD(M) value obtained by fitting is 2.05e-7( image 3 ), but as the concentration of TNFR1 increased, the signal value increased linearly without a saturation trend. Prove that His-Pgp3 and TNFR1 are non-specific binding ( Figure 4 ).

Embodiment 3

[0055] Example 3 Cell Apoptosis Rate Detection

[0056] 1.Hoechest 33258 detection of apoptosis rate

[0057] Remove the old culture medium in the 24-well plate, add 1ml PBS buffer to each well to wash the cells 2-3 times, remove the PBS buffer; add 4% paraformaldehyde to each well to fix for 15-20min; wash with PBS buffer 3 times, each time 3 to 5 minutes each time; Dilute Hoechst 33258 stock solution 100 times with physiological saline or PBS buffer solution, which is the working solution. Add working solution to the 24-well plate, 200 μl working solution per well, and stain in the dark for 3-5 minutes at room temperature; remove Hoechst 33258 staining solution, wash with PBS buffer three times, 3-5 minutes each time; observe cell apoptosis under a fluorescent microscope death situation.

[0058] Experimental results such as Figure 5 As shown, compared with the positive control group, most of the nuclei in the mixed group were uniformly light blue ( Figure 5 The middle...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of chlamydia protein pgp3 in preparation of a medicine for inhibiting salpingitis. Experimental research proves that pgp3 can be specifically combined with TNF-alpha, TNF-alpha mediated host cell apoptosis can be effectively inhibited after combination, and it is guaranteed that the growth cycle of chlamydia in host cells is completed; the pgp3 can induce fallopian tube epithelial cells to generate inflammatory response, and can synergistically enhance the inflammatory response after being combined with TNF-alpha.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of chlamydia protein Pgp3 in the preparation of medicines for inhibiting oviduct inflammation. Background technique [0002] Chlamydia trachomatis is a Gram-negative obligate intracellular parasitic prokaryote that needs to live in host cells for growth and reproduction. Vaccination may be more effective than other biomedical interventions in controlling chlamydial infection, but due to the immunological properties of the reproductive tract and the infectious properties of chlamydia on mucosal and epidermal cells, vaccines that are effective in inducing mucosal and systemic protective responses are unlikely to be effective. Not making good progress. [0003] Inflammatory reaction is a common reaction after Chlamydia trachomatis infection of the reproductive tract. It usually manifests as dilated fallopian tubes, hydrops, and infiltration of neutro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P15/08A61P31/04
CPCA61K45/00A61P15/08A61P31/04
Inventor 侯淑萍
Owner GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com